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Abstract
Dengue is a mosquito-transmitted viral infectious disease that is endemic to 110 countries spanning
tropical and subtropical regions. While infection is typically asymptomatic, symptoms of the estimated
50-100 million clinical cases are often debilitating and occasionally life-threatening, resulting in as many
as 5 million hospitalisations annually. Consequently, the World Health Organization regards dengue as a
signiﬁcant global public health concern. Immense challenges exist in both formulating and constructing
an eﬃcacious vaccine for prophylaxis and in developing therapeutics for cure. Although there have been
numerous molecular studies of the interaction between host and virus, and the metabolic pathways of
several proteins are implicated in dengue virus replication, their biological signiﬁcance remains unclear. It is
important to consider clinical, immunopathological and epidemiological features to decipher the complexity
of disease and to unravel the mechanisms attributed to its progression. This editorial emphasises the critical
events causing vascular endothelial permeability, which underpins the manifestations in humans of dengue
haemorrhagic fever and dengue shock syndrome.
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Introduction
The dengue virus (DV) is a small, enveloped,
positive sense, single-stranded RNA virus belonging
to the family Flaviviridae and genus Flavivirus. It
is an arthropod-borne virus and is transmitted by
mosquitoes of the genus Aedes, principally A. aegypti
and A. albopticus. Dengue virus is related to other
ﬂaviviruses that also cause acute haemorrhagic
diseases globally, such as Japanese encephalitis
virus, West Nile virus and Yellow fever virus. Based
on neutralisation assays, there are ﬁve distinct
serotypes, DENV-1 to DENV-5, the last of which
was discovered only very recently [1]. The dengue
virus genome contains about 11,000 nucleotide
bases, which code for three structural proteins,
capsid protein C, membrane protein M and envelope
protein E, and seven other non-structural protein
molecules (NS1, NS2a, NS2b, NS3, NS4a, NS4b, NS5)
that are found only in infected host cells and are
required for replication of the virus.
Dengue infection is a major cause of disease in
the tropics and subtropics with a reported incidence
of more than 50 million clinical cases each year
among 2.5 billion individuals who live in areas of
transmission [2]. Infection with DENV serotypes
causes a repertoire of manifestations from febrile
illness, dengue fever (DF), to severe illness known as
dengue haemorrhagic fever (DHF) and dengue shock
syndrome (DSS) [3,4]. Symptoms of mild DF include
muscle pain (myalgia), headache, rash, swollen lymph
nodes (lymphadenopathy) and a reduced leukocyte
count (leukopenia) [5]. In addition to these, the
characteristic risk features of acquiring DHF and
DSS include haemorrhagic manifestations. Notably,
a reduced platelet count – thrombocytopenia – is
caused by a sudden increase in vascular leakage as a
consequence of elevated capillary permeability [6,7].
The mechanisms involved in disease severity
are still ambiguous. However, it has been noted
that an antibody-dependent enhancement (ADE) of
infection increases the likelihood of developing DHF
and DSS [8,9]. This occurs when non-neutralising
antiviral proteins facilitate virus entry into human
endothelial cells (EC), thereby increasing infectivity
of host cells. ADE may be observed when a person
who previously has been infected with one serotype
of DENV becomes infected with a diﬀerent serotype
months or even years later. The clinical course
of disease is more severe, with higher viraemia
compared to those in whom ADE has not developed
[9]. This explains the observation that while primary
infections cause mostly minor disease (typically DF)
in children, secondary infection is more likely to be
associated with severe disease, DHF and/or DSS, in
individuals of all ages.
Factors involved in vascular permeability during
infection
Recent research on vascular leakage as a
consequence of severe dengue disease attributes
the cause to a mechanism of molecular mimicry by
cross-reaction of anti-DV NS1 antibodies with human
EC and platelets which leads to their dysfunction
2and thereby interference with haemostasis [10,11].
Protein disulﬁde isomerase (PDI), an endoplasmic
reticulum/Golgi-bound chaperone which ordinarily
plays a key role in protein folding in eukaryotes
[12], has been demonstrated to interact with anti-
DV-2 NS1, while PDI is also involved in platelet
aggregation, consequently hypothesized to have
implications for severe dengue pathogenesis [11].
A number of studies indicate that extracellular
surface-expressed PDI is implicated in virus entry
by modifying viral proteins [13-16]. It has also been
reported that DENV-2 uses PDI as a receptor to
gain entry into EC [17]. However, with the other
four dengue serotypes the role of PDI is yet to be
explored. The in vitro culture of EC may contribute to
discovery of a novel early phase biological marker for
severe dengue disease.
Levels of expression by EC and platelets
of various cell adhesion molecules, including
platelet endothelial cell adhesion molecule (PCAM),
platelet (P)-selectin, endothelial (E)-selectin, vascular
endothelial (VE)-cadherin, and of other factors such
as matrix metalloproteinase (MMP) enzymes, are
known to be altered by viral infection. Consequently,
this leads to vascular leakage and causes impairment
of haemostasis and coagulation of blood [7,18-21].
There are several soluble factors and mediators
which are thought to alter expression in patients with
severe dengue infections. These include vascular
endothelial growth factor (VEGF), granulocyte-
macrophage colony-stimulating factor (GMCSF),
monocyte chemoattractant protein 1 (MCP-1),
macrophage migration inhibitory factor (MIF),
thrombopoietin, vascular cell adhesion molecule
1 (VCAM-1), intercellular adhesion molecule 1
(ICAM-1), MMPs, thrombomodulin, endothelial (E)-
selectin, tissue factor (TF), plasminogen activator
inhibitor 1 (PAI-1) and tissue plasminogen activator
(TPA) [18,20,22]. Potential biomarkers such as
interleukin (IL)-10, ﬁbrinogen, complement C4A,
immunoglobulin subclasses, tropomyosin, and three
isoforms of albumin are thought to be involved in
DHF [23].
In Andes virus-induced hanta haemorrhagic fever,
binding of VEGF to VEGF-receptor (R)2 may be
blocked using an antibody to VEGF-R2 activation,
resulting in inhibition of the Andes virus-induced VE-
cadherin reduction [24]. A similar approach can be
taken to examine factors that may inhibit or reduce
EC permeability in DHF/DSS which could in turn serve
as a potential immunotherapeutic target for the
treatment of the disease.
Role of Non-Structural (NS) protein 1 in
pathogenesis of disease
The complement system is an integral component
of the innate immune response. During the
defervescence phase of dengue infection increased
leakage of plasma is associated with raised detection
of activation products such as C3a and C5a in the
plasma followed by increased usage and reduction
of complement components in patients with DSS
[25-27]. Complement components are also thought
to be activated due to the circulating soluble form
of dengue NS1 protein in the blood [28,29]. DV NS1
is reported to interact with complement regulatory
factors, for example clusterin, and thereby increase
vascular permeability [30]. Plasma levels of DV NS1
and terminal C5b-9 complement complexes are
correlated with disease severity. Large quantities
of NS1, complement anaphylatoxin C5a and the
terminal complement complex SC5b-9 are present in
pleural ﬂuids from DSS patients [31]. Recent ﬁndings
elucidate the function of the mannose-binding lectin
(MBL) pathway for controlling DV infections [29,32].
This activation of complement may also contribute to
vascular leakage and development of DHF and DSS.
Identiﬁcation of factors and mechanisms involved
may provide opportunities for development of
immunotherapeutics.
Host immune factors contribute to endothelial
dysfunction
Vascular dysfunction is associated with DHF and
DSS and is one of the hallmarks of disease
progression. In addition to direct damage caused
by the virus, immune responses of the host to DV
infection may also contribute to the pathogenesis
of disease. Our understanding of the important
events and mediators involved in DV infection,
such as antibody-dependent enhancement and
inﬂammatory cytokines, has built progressively over
many years but much of the molecular detail
remains to be elucidated [33,34]. In patients with
secondary DV infection with the same or a diﬀerent
pre-existing DENV serotype, neutralizing and non-
neutralizing antibodies appear to enhance viral
replication in Fc receptor (FcR)-bearing host cells,
notably macrophages and monocytes [33]. Enhanced
replication of virus particles in these target cells
is probably responsible for the high levels of
viraemia during the early stage of illness which
have been correlated with DHF incidence [35,36].
Cross-reactive antibodies against DENV NS1 that
cause EC damage have been attributed to nitric
oxide-mediated apoptosis [37]. Studies also show
that production of cytokines and chemokines such
as IL-6, IL-8 and MCP-1 increase after treatment
with anti-NS1 antibodies and by inhibition of the
eukaryotic transcription factor NF-κB in EC [38]. Apart
from auto-antibodies that are generated during
DV infection, CD4+ and CD8+ T-cell activation is
observed to be higher in patients with DHF compared
to those with mild DF [39]. T cells that are sensitized
during primary infection proliferate upon secondary
exposure to release pro-inﬂammatory cytokines such
as interferon gamma (IFN-γ) and tumour necrosis
factor alpha (TNF-α) [40], which can act directly on
vascular EC to cause plasma leakage.
The current consensus of opinion is that activated
T cells trigger a cascade of cytokines which target
the vascular endothelium and that this may be a
key factor responsible for vascular permeability [39].
Studies show that IFN-γ, TNF-α and IL-10 are elevated
in the sera of patients with DHF/DSS [41-43]. It is
observed that dengue-infected EC elicit high level
induction of T cells, B cells and mast cells and
secretion of cytokines B-cell activating factor (BAFF),
3chemokine (C-X-C motif) ligand (CXCL) 9/10/11,
chemokine (C-C motif) ligand 5 (CCL5) and IL-7, which
leads to capillary permeability, viraemia and immune
targeting of the endothelium [44].
T-cell responses during dengue virus infection
The hypothesis of ‘original antigenic sin’ of secondary
infection postulates that prior exposure to an
antigen leads to an alteration of immune response
that is skewed by the ‘memory’ of the primary
infection [45-47]. Several studies have indicated
that both CD4+ and CD8+ T cells aid in controlling
and resolving DV infection [47]. A recent cohort
study performed in Sri Lanka by Weiskopf et
al. has challenged this theory by demonstrating
during primary dengue infection that CD8+ T cells
responses are skewed but not impaired qualitatively
or quantitatively [48]; this also showed that the
magnitude of T-cell response linked to human
leukocyte antigen (HLA) alleles confers a reduction
in susceptibility to disease severity [47,48]. However,
the cohort considered for this study included adults
with ages between 18-60 years. There is evidence to
suggest that most children infected with DV progress
to severe manifestations of DHF [49]. Hence, immune
reactivity in juveniles may be expected to be
diﬀerent to that observed in adults. T-cell responses
across the DV proteome are most frequent to NS3
and both the amplitude of response in DHF and
disease severity are associated with high levels of
pro-inﬂammatory cytokines and reduced expression
by T cells of the marker of degranulation CD107a
[50]. In contrast, T-cell responses in DV-infected Thai
children showed low aﬃnity for the current infecting
serotype and higher aﬃnity for an earlier infecting
serotype, thereby supporting the hypothesis of
‘original antigenic sin’[51]. Therefore, much remains
to be unravelled about the role of T cells in DV
infection. Although there is mounting evidence of
HLA-linked CD8+ T-cell protection in DHF and/or
DSS it is arguably premature to challenge received
wisdom on the subject.
Conclusion
In addressing the aetiology of dengue infection, it
is important to understand what determines the
threshold of activation for development of DHF/DSS.
Establishing the role of PDI in dengue pathogenesis
could serve as a marker for early detection of
disease. Identifying and elucidating the role of
host immune factors associated with endothelial
cell permeability could open new windows to
determining immunomodulatory drug targets and
antiviral reagents for the successful management of
patients with DF, thereby preventing progression to
DHF/DSS. Characterization of the protective role of
HLA-linked CD8+ T-cell responses in both adults and
children should enable a better understanding of
immune responses to dengue infection. This may also
accelerate the development of safe and eﬀective
vaccines as well as to facilitate the creation of
humanised mouse models as a valuable resource for
further study.
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